Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$98.98 - $115.74 $27 Million - $31.6 Million
-273,100 Reduced 22.55%
937,800 $108 Million
Q2 2023

Aug 14, 2023

BUY
$96.34 - $112.38 $115 Million - $134 Million
1,193,200 Added 6741.24%
1,210,900 $125 Million
Q1 2023

May 15, 2023

SELL
$107.32 - $113.5 $28.5 Million - $30.2 Million
-265,900 Reduced 93.76%
17,700 $1.93 Million
Q4 2022

Feb 14, 2023

BUY
$62.39 - $113.8 $13.9 Million - $25.3 Million
222,700 Added 365.68%
283,600 $32.3 Million
Q3 2022

Nov 14, 2022

SELL
$58.92 - $84.67 $2.36 Million - $3.4 Million
-40,100 Reduced 39.7%
60,900 $3.77 Million

Others Institutions Holding HZNP

About Horizon Therapeutics Public Ltd Co


  • Ticker HZNP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 230,384,000
  • Description
  • Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...
More about HZNP
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.